Logo-jcvtr
Submitted: 13 Oct 2019
Accepted: 07 May 2020
ePublished: 17 May 2020
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Cardiovasc Thorac Res. 2020;12(2): 140-144.
doi: 10.34172/jcvtr.2020.23
  Abstract View: 84
  PDF Download: 52

Short Communication

Comparison of apolipoprotein-A1 levels between paroxysmal atrial fibrillation patients and healthy subjects

Tufan Çınar 1 * ORCID logo, Veysel Ozan Tanık 2, Kadir Gürkan 3

1 Health Sciences University, Sultan Abdülhamid Han Training and Research Hospital, Department of Cardiology, Istanbul, Turkey
2 Ankara Dışkapı Yıldırım Beyazıt Training and Research Hospital, Department of Cardiology, Ankara, Turkey
3 Health Sciences University, Siyami Ersek Training and Research Hospital, Department of Cardiology, Istanbul, Turkey
*Corresponding Author: Tufan Çınar, Email: drtufancinar@gmail.com

Abstract

Introduction: Studies found that the inflammation plays a key role in the pathogenesis of paroxysmal atrial fibrillation (PAF). It is well-known that apolipoprotein-A1 (Apo-A1) demonstrates antiinflammatory and anti-oxidant properties in a healthy physiological system. In the present study, we aimed to determine whether there is any difference of Apo-A1 levels in patients with PAF and healthy subjects.

Methods: In this prospective cohort study, we enrolled a total of 35 PAF patients and 34 comparable healthy participants. Apo-A1 levels were measured from each subject using an immunophelometric method. All enrolled subjects were followed-up for one year during the study period.

Results: Serum high-sensitivity C-reactive protein (hs-CRP) levels were statistically higher in PAF patients compared to healthy subjects (1.54±1.99 vs. 1.06±2.01, P= 0.016, respectively). Of note, patients with PAF had lower Apo-A1 levels (1.84±0.74 vs. 2.55±0.44, P= 0.001, respectively). There was no statistical difference between the groups in terms of apolipoprotein-B levels (1.08±0.36 vs. 0.99±0.38, P= 0.339, respectively). We did not find any correlation between Apo-A1 levels and PAF attacks in the study.

Conclusion: The main finding of this study was that Apo-A1 levels were significantly lower in PAF patients compared to healthy participants. Based on our results, we considered that Apo-A1 may have a key role in the pathogenesis of PAF.

Keywords: Paroxysmal Atrial Fibrillation, Apolipoprotein-A1, Inflammation
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 84

Your browser does not support the canvas element.


PDF Download: 52

Your browser does not support the canvas element.